Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis

Journal of Nutrition

Volumn 137, Issue 5, 2007, Pages 1222-1228

  Daddaoua, Abdelali ^a   Martínez Plata, Enrique ^a   López Posadas, Rocío ^a   Vieites, José María ^a   González, Mercedes ^a   Requena, Pilar ^a   Zarzuelo, Antonio ^a   Suárez, María Dolores ^a   Sánchez De Medina, Fermín ^a   Martínez Augustin, Olga ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE HEXOSE CORRELATED COMPOUND; ALKALINE PHOSPHATASE; GLUTATHIONE; HAPTEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MUCIN 2; MUCIN 4; MYELOPEROXIDASE; PREBIOTIC AGENT; TREFOIL PEPTIDE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASIDIOMYCETES; BODY WEIGHT; COLITIS; COLON FLORA; COLON INJURY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FOOD INTAKE; NONHUMAN; PROTEIN EXPRESSION; RAT;

CLOSTRIDIA; LOTUS; RATTUS;

EID: 34247872830     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/137.5.1222     Document Type: Article

References (41)

1. Kidd PM. The use of mushroom glucan and proteoglycans in cancer treatment. Altern Med Rev. 2005;5:4-27.
2. Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, et al. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. J Hepatol. 2002;37:147-50.
3. Matsushita K, Kuramitsu Y, Ohiro Y, Obara M, Kobayashi M, Li YQ, Hosokawa M. Combination therapy of active hexose correlated compound plus UFT significantly. Anticancer Drugs. 1998;9:343-50.
4. Ye SF, Ichimura K, Wakame K, Ohe M. Suppressive effects of active hexose correlated compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress. Life Sci. 2003;74:593-602.
5. Ghoneum M, Wimbley M, Salem F, McKlain A, Attallah N, Gill G. Immunomodulatory and anticancer effects of active hemicellulose compound (AHCC). Int J Immunother. 1995;11:23-8.
6. Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher basidiomycete mushrooms: a modern perspective. Crit Rev Immunol. 1999;19:65-9.
7. Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, Yin Z. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother. 2005;55:1258-66.
8. Bass NM. It could have been something they ate: functional food and the treatment of liver cancer. J Hepatol. 2002;37:147-50.
9. Wakame A. Protective effects of active hexose correlated compound (AHCC) on the onset of diabetes induced by streptozotocin n the rat. Biomed Res. 1999;20:145-52.
10. Sun B, Wakame K, Mukoda T, Toyoshima A, Kanazawa T, Kosuna K. Preventive effects of AHCC on carbon tetrachloride induced liver injury in mice. Nat Med. 1997;51:310-5.
11. Aviles H, Belay T, Vance M, Sun B, Sonnefeld G. Active hexose correlated compound enhances the immune function of mice in the hindlimb-unloadingmodel of spaceflight conditions. J Appl Physiol. 2004; 97:1437-44.
12. Aviles H, Belay T, Fountain K, Vance M, Sun B, Sonnenfeld G. Active hexose correlated compound enhances resistance to Klebsiella pneumoniae infection in mice in the hindlimb-unloading model of spaceflight conditions. J Appl Physiol. 2003;95:491-6.
13. Ye SF, Wakame K, Ichimura K, Matsuzaki S. Amelioration by active hexose correlated compound of endocrine disturbances induced by oxidative stress in the rat. Endocr Regul. 2004;38:7-13.
14. Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. Clin Sci (Lond). 2004;107:331-41.
15. Thompson-Chagoyan OC, Maldonado J, Gil A. Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr. 2005;24:339-52.
16. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology. 2000;118:S68-82.
17. Obermeier F, Strauch UG, Dunger N, Grunwald N, Rath HC, Herfarth HH, Scholmerich J, Falk W. In vivo CpG DNA/ TLR9 interaction induces regulatory properties in CD4+CD62L+-T-cells which prevent intestinal inflammation in the SCID-transfer model of colitis. Gut. 2005;54:1428-36.
18. Daddaoua A, Puerta V, Requena P, Martinez-Ferez A, Guadix E, Sanchez de Medina F, Zarzuelo A, Suarez MD, Boza JJ, et al. Goat milk oligosaccharides are anti-inflammatory in rats with hapten-induced colitis. J Nutr. 2006;136:672-6.
19. Hoentjen F, Welling GW, Harmsen HJ, Zhang X, Snart J, Tannock GW, Lien K, Churchill TA, Lupicki M, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis. 2005;11:977-85.
20. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96:795-803.
21. Palmen MJ, Dieleman LA, van der Ende MB, Uyterlinde A, Pena AS, Meuwissen SG, van Rees EP. Non-lymphoid and lymphoid cells in acute, chronic and relapsing experimental colitis. Clin Exp Immunol. 1995;99:226-32.
22. Rivera E, Flores I, Rivera E, Appleyard CB. Molecular profiling of a rat model of colitis: validation of known inflammatory genes and identification of novel disease-associated targets. Inflamm Bowel Dis. 2006;12:950-66.
23. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87: 1344-50.
24. Akerboom TP, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol. 1981;77:373-82.
25. Sanchez de Medina F, Martinez-Augustin O, Gonzalez R, Ballester I, Nieto A, Galvez J, Zarzuelo A. Induction of alkaline phosphatase in the inflamed intestine: a novel pharmacological target for inflammatory bowel disease. Biochem Pharmacol. 2004;68:2317-26.
26. Blaut M. Relationship of prebiotics and food to intestinal microflora. Eur J Nutr. 2002;41 Suppl 1:I11-6.
27. Knol J, Boehm G, Lidestri M, Negretti F, Jelinek J, Agosti M, Stahl B, Marini A, Mosca F. Increase of faecal bifidobacteria due to dietary oligosaccharides induces a reduction of clinically relevant pathogen germs in the faeces of formula-fed preterm infants. Acta Paediatr. 2005;Suppl 94:31-3.
28. Bakker-Zierikzee AM, Alles MS, Knol J, Kok FJ, Tolboom JJ, Bindels JG. Effects of infant formula containing a mixture of galacto- and fructo-oligosaccharides or viable Bifidobacterium animalis on the intestinal microflora during the first 4 months of life. Br J Nutr. 2005; 94:783-90.
29. Dinoto A, Suksomcheep A, Ishizuka S, Kimura H, Hanada S, Kamagata Y, Asano K, Tomita F, Yokota A. Modulation of rat cecal microbiota by administration of raffinose and encapsulated Bifidobacterium breve. Appl Environ Microbiol. 2006;72:784-92.
30. Morrow AL, Ruiz-Palacios GM, Jiang X, Newburg DS. Human milk glycans that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea. J Nutr. 2005;135:1304-7.
31. Shoaf K, Mulvey GL, Armstrong GD, Hutkins RW. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells. Infect Immun. 2006;74:6920-8.
32. Coppa GV, Zampini L, Galeazzi T, Facinelli B, Ferrante L, Capretti R, Orazio G. Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: Escherichia coli, Vibrio cholerae, and Salmonella fyris. Pediatr Res. 2006;59:377-82.
33. McHugh KJ, Collins SM, Weingarten HP. Central interleukin-1 receptors contribute to suppression of feeding after acute colitis in the rat. Am J Physiol. 1994;266:R1659-63.
34. El-Haj T, Poole S, Farthing MJ, Ballinger AB. Anorexia in a rat model of colitis: interaction of interleukin-1 and hypothalamic serotonin. Brain Res. 2002;927:1-7.
35. McCormack G, Moriarty D, O'Donoghue DP, McCormick PA, Sheahan K, Baird AW. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res. 2001;50:491-5.
36. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol. 1993;54:167-227. 73.
37. D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006;8:506-12.
38. Schley PD, Field CJ. The immune-enhancing effects of dietary fibres and prebiotics. Br J Nutr. 2002;87 Suppl 2:S221-30.
39. Podolsky DK. Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. J Gastroenterol. 2000;35 Suppl 12:69-74.
40. Buisine MP, Desreumaux P, Leteurtre E, Copin MC, Colombel JF, Porchet N, Aubert JP. Mucin gene expression in intestinal epithelial cells in Crohn's disease. Gut. 2001;49:544-51.
41. Hartley MG, Hudson MJ, Swarbrick ET, Grace RH, Gent AE, Hellier MD. Sulphasalazine treatment and the colorectal mucosa-associated flora in ulcerative colitis. Aliment Pharmacol Ther. 1996;10:157-63.